Literature DB >> 10779196

Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck.

F Riedel1, K Götte, J Schwalb, C Schäfer, K Hörmann.   

Abstract

Vascular endothelial growth factor (VEGF) has potent angiogenic activity and has been identified in a wide variety of malignancies, including head and neck squamous cell carcinoma (HNSCC). The tumour-suppressor gene p53 has been thought to regulate VEGF. Cryostat sections of 33 head and neck squamous cell carcinomas (HNSCC) were immunostained for VEGF using a standard streptavidin-biotin complex procedure. To evaluate angiogenesis, microvascular density was counted by staining endothelial cells immunohistochemically using anti-vWF monoclonal antibody. The p53 gene status was analysed using a PCR-SSCP analysis and direct sequencing. VEGF positive staining was detected in 18 (55%) out of 33 tumours. VEGF immunoreactivity did not correlate with the main clinicopathological characteristics of the patients (localization, T-stage, N-status, histological grading). Statistical analysis gave a clear correlation between the tumour vascularity and the VEGF protein expression (p = 0.0036). VEGF negative tumours showed a lower mean number of microvessels per microscopic field (60.3 +/- 15.5) than VEGF positive tumours (79.6 +/- 22.9). P53 mutations were identified in 12 (36.4%) of 33 tumours. The association of p53 mutations and VEGF expression level was significant (0.027). The higher microvessel density in VEGF positive tumours supports the importance of VEGF for tumour angiogenesis in HNSCC. Our results support the hypothesis of a p53 regulation on the angiogenic process through a VEGF up-regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779196     DOI: 10.1080/00016480060203334

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  9 in total

1.  Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; P E Thorpe; R A Brekken; S Konstantinos; G Fountzilas; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.

Authors:  Muhammad U Rashid; Sidra Gull; Kashif Asghar; Noor Muhammad; Asim Amin; Ute Hamann
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  MRI texture analysis predicts p53 status in head and neck squamous cell carcinoma.

Authors:  M Dang; J T Lysack; T Wu; T W Matthews; S P Chandarana; N T Brockton; P Bose; G Bansal; H Cheng; J R Mitchell; J C Dort
Journal:  AJNR Am J Neuroradiol       Date:  2014-09-25       Impact factor: 3.825

4.  Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.

Authors:  Panayiotis A Kyzas; Dimitrios Stefanou; Anna Batistatou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.

Authors:  Larissa Sweeny; Terence M Zimmermann; Zhiyong Liu; Eben L Rosenthal
Journal:  Oral Oncol       Date:  2012-07-13       Impact factor: 5.337

6.  MRI features predict p53 status in lower-grade gliomas via a machine-learning approach.

Authors:  Yiming Li; Zenghui Qian; Kaibin Xu; Kai Wang; Xing Fan; Shaowu Li; Tao Jiang; Xing Liu; Yinyan Wang
Journal:  Neuroimage Clin       Date:  2017-10-29       Impact factor: 4.881

7.  Characterization of the Expression of Angiogenic Factors in Cutaneous Squamous Cell Carcinoma of Domestic Cats.

Authors:  Erwin Kristobal Gudenschwager-Basso; Valentina Stevenson; Dan Phillip Sponenberg; Thomas E Cecere; William R Huckle
Journal:  Vet Sci       Date:  2022-07-21

8.  A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine.

Authors:  Mohammad Reza Eskandarion; Zahra Tizmaghz; Bahram Andalib; Nasser Parsa; Seyed Amir Hossein Emami; Reza Shahsiah; Mohammad Ali Oghabian; Reza Shirkoohi
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

9.  P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

Authors:  Rabin Said; David S Hong; Carla L Warneke; J Jack Lee; Jennifer J Wheler; Filip Janku; Aung Naing; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Oncotarget       Date:  2013-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.